In MG-63 cells incubated with Oridonin for 24 h, the cell viability IC50 was 12.29 ± 1.02 μM. In primary peritoneal macrophages from ApoE−/− mice, Oridonin decreased ox-LDL-induced lipid deposition compared with cultures without Oridonin. In K562 cells, Oridonin at 20 μM for 2 h substantially inhibited BCR-ABL activity. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell viability in MG-63 cells
Cell-based study · MG-63 [1]
After 24 h of treatment, the IC50 (the concentration of drug inhibiting 50% of cells) value of MG-63 cells was 12.29 ± 1.02 μM.
Literature-Reported Treatment Conditions
- Exposure duration
- 24 h
- Method
- incubation with oridonin
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Oridonin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Oridonin induced apoptosis in human osteosarcoma cells (S2, S3); Materials and methods > MTT assay (S135); Materials and methods > Statistical analysis (S180)
cell viability: cell viability; comparator: untreated controls — Results > Oridonin induced apoptosis in human osteosarcoma cells (S2, S3)
Oridonin decreases lipid deposition in primary peritoneal macrophages
Cell-based study · primary peritoneal macrophages from ApoE−/− mice [2]
Primary peritoneal macrophages from ApoE−/− mice were cultured with Oridonin at 2.5 μM and 5 μM for 48 h and compared with cultures without Oridonin. Oil red O staining showed that Oridonin decreased ox-LDL-induced lipid deposition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2.5 μM and 5 μM
- Exposure duration
- 48 h
- Method
- cultured
- Co-treatment
- Other interventions in this design: human oxidized low-density lipoprotein (ox-LDL) 50 μg/mL; BBL thioglycollate, Brewer modified 1 mL 4%. Compound effect isolated by the comparison: with or without oridonin.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Oridonin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Isolation of peritoneal macrophages (S23, S26); Results > Oridonin inhibits lipid uptake and enhances lipid efflux in macrophages in vivo and in vitro (S112, S113)
Oil red O staining: Oil red O staining; comparator: without oridonin — Results > Oridonin inhibits lipid uptake and enhances lipid efflux in macrophages in vivo and in vitro (S113)
Oridonin inhibits BCR-ABL activity in K562 cells
Cell-based study · K562 cells [3]
K562 cells were treated with Oridonin at 20 μM for 2 h, with DMSO as the control. Oridonin substantially inhibited BCR-ABL activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 μM
- Exposure duration
- 2 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Oridonin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Oridonin induces rapid depletion of the BCR-ABL fusion protein (S3); Materials and Methods > Cell lines and reagents (S66); Figure 1 legend (S133, S134)
BCR-ABL/C-ABL activity: BCR-ABL/C-ABL activity; comparator: DMSO (Ctrl) — Results > Oridonin induces rapid depletion of the BCR-ABL fusion protein (S3); Figure 1 legend (S134)